Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Ixekizumab shows sustained improvements in pain and fatigue at 3 years

Ixekizumab shows sustained improvements in pain and fatigue at 3 years

Patients suffering from psoriatic arthritis often report pain and fatigue. Previous studies have demonstrated improvements in pain and fatigue for up to 2 years with ixekizumab in patients who had an inadequate response or intolerance to tumour necrosis factor inhibitors (TNFi). At the EULAR 2020 meeting, Prof. Ana-Maria Orbai (Johns Hopkins University School of Medicine, USA) presented the 3-year follow-up outcomes of the SPIRIT-P2 trial [1-3].

The 156-week, phase 3 SPIRIT-P2 study included patients who met the Classification Criteria for Psoriatic Arthritis (CASPAR) and had an inadequate response or intolerance to 1 or 2 TNFi. Although there was a placebo group through week 24, this data was derived only from patients in the intent-to-treat population randomised to ixekizumab at baseline. The 244 participants were randomised to 80 mg subcutaneous ixekizumab every 2 (Q2W; n=123) or 4 weeks (Q4W...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on